Nymox Pharmaceutical Corporation (NYMXF)
| Market Cap | 21.01K -99.6% |
| Revenue (ttm) | n/a |
| Net Income | -4.49M |
| EPS | -0.05 |
| Shares Out | 105.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 45,000 |
| Open | 0.0002 |
| Previous Close | 0.0002 |
| Day's Range | 0.0002 - 0.0120 |
| 52-Week Range | 0.0002 - 0.1999 |
| Beta | 14.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About Nymox Pharmaceutical
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment and prevention of Alzheimer’s disea... [Read more]
Financial Performance
Financial StatementsNews
Nymox's Nymozarfex(TM) Newly Available for Prostate Treatments for Medical Tourists in Collaboration with the Global Alliance of Regenerative Medicine on Roatan Island in the Caribbean
IRVINE, CA / ACCESS Newswire / June 17, 2026 / Nymox Pharmaceutical Corporation ("Nymox", "The Company") (OTCQB:NYMXF) is pleased to announce that it has entered into a formal agreement for its drug t...
NYMOX Provides Current Update
IRVINE, CA / ACCESS Newswire / June 2, 2026 / Nymox Pharmaceutical Corporation ("Nymox", "The Company") (OTCQB:NYMXF) reports that its plans for Nymozarfex (TM) are currently focused on re-submission ...
NYMOX Provides Recent Updates
IRVINE, CA / ACCESS Newswire / March 27, 2026 / Nymox Pharmaceutical Corporation ("Nymox", "The Company") (OTCQB:NYMXF) will be shortly updating the Board of Directors. Patrick Doody has retired from ...
Nymox Announces Dismissal of Delaware Action Against Ascella
IRVINE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Nymox announces that it dismissed the Delaware matter pending against Ascella on March 7, 2025. A number of factors caused the company to reconsider ...
Nymox resumes trading with listing on OTCQB
Nymox (NYMXF) Pharmaceutical Corporation announced that the Company’s stock has resumed trading under the symbol NYMXF on the Over the Counter QB Venture Market. This is a higher level tier…
NYMOX Announces Trading Resumed and New Listing on OTCQB Market
IRVINE Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the Company's stock has resumed trading under the symbol NYMXF on t...
Nymox Announces Filing of Annual Report
IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to report that it filed its Annual Report with the Security and Exchange Com...
Nymox Annual Report
IRVINE, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its Annual Report is and has been in progress since late February,...
Nymox Required to Resubmit Application to DKMA
IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its MAA submission to the Danish Medicines Agency (DKMA) has run o...
Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages
IRVINE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) is pleased to report that the Bahamas Supreme Court has issued a formal Order offici...
Nymox December 27 Message to Shareholders
IRVINE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to provide this end-of-the year message to shareholders.
Nymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and Others
IRVINE, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the California Superior Court, Orange County (OCSC) has issued an ...
Nymox Pharmaceutical Corporation Sues AscellaHealth For $250 Million
IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- This week, Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) was forced to file a lawsuit in California Superior Court, Orange County, ...
NYMOX REPORTS: Bahamian Court Today Suspends Order of October 3, 2023 Rendering Riley-Lanham and Accomplices Planned Vote Unauthorized
IRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox” or the “Company”) [OTC Markets---NYMXF] is pleased to announce that the Bahamian Court (Senior Justice Debor...
NYMOX REPORTS NOTICE: California Court Issued A Temporary Restraining Order Enjoining Lanham, Riley, Cutler And Their Nevada Company After Court Hearing In Santa Ana, California, November 2, 2023
Ex-Employees and Agents, and those working in concert with them, are ordered by a California Court to stop using, disclosing, relying on, or otherwise make publicly available Nymox privileged informat...
IMPORTANT MESSAGE TO NYMOX SHAREHOLDERS: NYMOX Cautions Against Unauthorized Improper Shareholder Meeting and Unauthorized Unregistered Solicitations
IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- The following is Nymox's response to an unauthorized shareholder meeting: Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company” or “Ny...
IMPORTANT NOTICE: NYMOX Cautions Shareholders Not to Take Calls or Participate in Unauthorized Improper Shareholder Meeting
IRVINE Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- The following is Nymox's response to an unauthorized shareholder meeting: Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company” or “Nym...
Notice: Nymox Informs Its Shareholders Not to Take Calls or Participate in An Unauthorized and Improper Shareholder Meeting
IRVINE, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- The following is Nymox's response to an unauthorized shareholder meeting: Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) warns...
Nymox Reports New NYMOZARFEX Marketing Application is Accepted For Review
IRVINE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce that the Company's recent submission of Fexapotide Trifl...
The Committee to Restore Nymox Shareholder Value Sends Letter to Nymox Pharmaceutical Shareholders and Issues Proxy Materials for Upcoming Special Meeting
CARSON CITY, Nev. & LONDON--(BUSINESS WIRE)--THE COMMITTEE TO RESTORE NYMOX SHAREHOLDER VALUE SENDS LETTER TO NYMOX PHARMACEUTICAL SHAREHOLDERS.
Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH
IRVINE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce today that a new formal submission has been made by the...
Nymox Reports Completion of $2 Million Private Placement
IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the completion of its recently reported private placemen...
Nymox Announces $2 Million Private Placement
IRVINE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce an investment of US $2.0 million for 2 million shares at...
Nymox's 3-month ex-CFO was Awarded an Unauthorized and Undisclosed Treasury Directive for 100,000 Shares of Nymox Stock Without the Knowledge or Approval of the Nymox Board or Nymox's CEO
Ex-CFO Provided to Nymox Before Appointment as CFO a Personal Resume with False Claim of Securing USD 62.5 million at his Previous Company Ex-CFO Provided to Nymox Before Appointment as CFO a Personal...